Justin Coffeen’s path through clinical research has taken him across three distinct therapeutic areas: orthopedics, oncology, and hepatology. Each requires a different clinical vocabulary, a different understanding of disease progression, and a different approach to participant management. Moving across them is a process of deliberate learning.
Starting in Orthopedics
Orthopedics was the natural entry point given Justin Coffeen’s clinical background. As a chiropractic physician with training in sports injury management, rehabilitation, and Functional Capacity Evaluations, he came to orthopedic research with an existing vocabulary. He understood the mechanics being studied, the clinical outcomes being measured, and the populations being enrolled. That foundation made it easier to engage with protocols, to follow adverse event reporting for musculoskeletal conditions, and to communicate meaningfully with investigators.
Orthopedic trials often involve participant-reported outcomes — pain scales, functional assessments, quality of life measures. The work Justin Coffeen had done in clinical practice with chronic pain patients and functional evaluation shaped how he facilitated those assessments. Participant-reported data is only as reliable as the collection process, and the collection process depends on how well the coordinator understands what the tool is trying to capture.
The Transition to Oncology
Oncology represented a significant shift. The therapeutic area involves different disease mechanisms, different endpoints, different adverse event profiles, and a participant population that is managing a serious diagnosis alongside their study participation. The clinical vocabulary is different — protocols reference tumor response criteria, progression-free survival, safety parameters specific to oncologic treatments. The consent process carries additional weight because the decisions participants are making have larger consequences.
Moving into oncology research required building a working knowledge of a new area: understanding the mechanisms of the therapies being studied, the expected and unexpected adverse events, the regulatory requirements specific to oncology trials. That process is familiar to anyone who has worked across therapeutic areas. The vocabulary changes. The approach to learning it does not.
Working in Hepatology
Hepatology added a third clinical domain. Liver disease studies involve different disease progression markers, different patient populations, and different safety monitoring requirements. A participant with hepatic impairment may process study medication differently than the general population, and the safety parameters around liver function tests require particular attention. Understanding what you are looking at in laboratory data — and recognizing when a value crosses a threshold that requires action — is not something that transfers automatically from one therapeutic area to another.
What does transfer is the practice of learning a new therapeutic area systematically: reading the protocol and its background documentation carefully, understanding the disease mechanism well enough to follow the scientific rationale for the study design, and learning the specific adverse event profile before enrollment begins rather than during it.
The Value of Cross-Area Experience
Working across orthopedics, oncology, and hepatology has produced a research professional with broader exposure than someone who has spent the same number of years in a single area. That breadth has real value. Different therapeutic areas use different trial designs, different regulatory approaches, and different monitoring standards. Familiarity with that variation makes it easier to adapt when working with a new sponsor, a new protocol, or a new site team.
For Justin Coffeen, the common thread across therapeutic areas is GCP. The protocol, the source documents, the consent process, the adverse event reporting, the communication with sponsors and monitors — these follow the same framework regardless of whether the study is in orthopedics or oncology. The therapeutic area content changes. The research discipline does not.
Read more about what GCP compliance looks like across therapeutic areas, or about communication and coordination in multi-site research. Learn more about Justin Coffeen.